> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Entrada Therapeutics’ DMD Drug Remains on Hold
- URL: https://www.fdaweb.com/entrada-therapeutics-dmd-drug-remains-on-hold/
- Published: 2023-11-22T12:00:00.000Z
- Updated: 2026-09-14T14:16:54.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5155847

Entrada Therapeutics says that despite providing additional information to FDA, an ongoing clinical hold against the company’s Phase 1 trial of ENTR-601-44 in Duchenne muscular dystrophy (DMD) patients remain in effect. “Importantly, the information that was submitted to the FDA supported the initiation of the Phase 1 clinical trial in the United Kingdom in 9/2023,” the company says. ENTR-601-44-101 clinical data are expected in the second half of 2024, and the company plans to re-engage FDA to discuss next steps in “due course,” it adds.

ENTR-601-44 is described as a proprietary endosomal escape vehicle (EEV)-conjugated phosphorodiamidate morpholino oligomer (PMO). “Each EEV-PMO therapeutic candidate has an oligonucleotide sequence designed and optimized for the specific subpopulation of interest,” the company says. ENTR-601-44 is reportedly designed to address the underlying cause of Duchenne due to mutated or missing exons (exon 44) in the DMD gene.